Work

ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Year: 2026

Type: conference-abstract

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps7100

Authors: Anna Chen, Jennifer Ann Woyach, John Francis Seymour, Danielle M. Brander, Deborah Marie Stephens, Neil E. Kay, Fenlai Tan, Yi Chen, Stephen Patrick Anthony, Kewei Shang, Yue Shen, Yejiang Lou, John C. Byrd

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Peter MacCallum Cancer Centre, Duke University Health System, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Mayo Clinic, Onconova Therapeutics (United States), Presage Biosciences (United States), UPMC Hillman Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162669704

Cites:

Cited by:

Related to: